FTC Extends Warning Letters Over 'Junk' Patents To Ozempic And Other Drugs

By Maaisha Osman / April 30, 2024 at 6:15 PM
The Federal Trade Commission (FTC) sent a second wave of warning letters to 10 additional companies for submitting what it deems “junk” patent listings in FDA’s Orange Book, including patents for Novo Nordisk’s blockbuster drug Ozempic and other drugs for diabetes, weight loss, asthma and chronic obstructive pulmonary disease (COPD). Industry experts say FTC’s latest move, coming on the heels of similar warnings to makers of inhaler products for using device patents to delay generic competition, will spur plaintiffs to...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.